Argenx, NL0010832176

Argenx stock gets Bernstein Buy rating as target is set

Published on 11/19/2026 at 10:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx stock received a Buy rating from Bernstein analyst Justin Smith. The analyst set a 914 euro price target on November 18.

Analyst signal for argenx

  • Bernstein analyst Justin Smith maintained a Buy rating for argenx.
  • The company continues to attract attention as investors assess its commercial growth and immunology pipeline.
Argenx, NL0010832176, Illustration mit AI erstellt.

On Wednesday, November 18, 2026, Bernstein analyst Justin Smith maintained a Buy rating on argenx and set a 914 euro price target, Markets Insider reported. The action gives investors a fresh sell-side view of the immunology company after its recent strategic updates.

Bernstein keeps positive stance

Smith's recommendation remained Buy rather than changing to a new rating. The 914 euro target places the analyst's published valuation above argenx's Lang & Schwarz quote during Thursday morning trading, although the two figures represent different market references and are not a forecast of a short-term move.

Argenx stock traded at 856.60 euros on Lang & Schwarz at 10:01 CET on Thursday, November 19, 2026. The quote provides the latest available trading reference for the European-listed shares during the reporting window.

The analyst call comes as argenx broadens its growth agenda around VYVGART and its wider immunology pipeline. At the Jefferies Global Healthcare Conference on November 17, management outlined potential launches and longer-term development work beyond the company's established FcRn franchise. That conference discussion was reported separately and does not change the rating action announced by Bernstein.

Argenx stock at a glance

  • Company: argenx SE
  • ISIN: NL0010832176
  • Analyst: Bernstein, Justin Smith
  • Rating: Buy
  • Price target: 914 euros
  • Lang & Schwarz quote: 856.60 euros at 10:01 CET, November 19, 2026

The AEX index offers the relevant broader Dutch-market context for investors following argenx and other Amsterdam-listed companies. Current market reports provide wider market coverage.

More news and analyses on argenx stock

Disclaimer...
en | NL0010832176 | ARGENX | boerse | 70534823 | bgmi